Therapy News and Research

RSS

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome at Digestive Disease Week 2010 in New Orleans, Louisiana.

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Study to assess therapy for feeding difficulties in kids

It is a common complaint of many mothers that their children refuse food. Now Australian scientists are looking for answers to this problem in order to reduce the increase in the number of malnourished children who need medical help because of their picky eating.

6 May 2010

Researchers discover link between sporadic and familial forms of ALS

Researchers from Northwestern University Feinberg School of Medicine have discovered a link between sporadic and familial forms of amyotrophic lateral sclerosis, a neurodegenerative disease also known as Lou Gehrig's disease.

6 May 2010

Savient Pharmaceuticals' total revenues reach $1.1M in first-quarter 2010

Savient Pharmaceuticals, Inc. announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA by the U.S. Food and Drug Administration (assuming KRYSTEXXA is approved) would be the best way to realize the full commercial potential of KRYSTEXXA on a global basis and would be the optimal outcome for the Company's shareholders and other stakeholders.

6 May 2010

Novocell is now ViaCyte

Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Cardiogenesis reports 13% increase in first-quarter 2010 revenue

Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of cardiac patients suffering from severe angina, today reported financial results for its first quarter ended March 31, 2010.

6 May 2010

New test indicates bone marrow cell therapy may benefit MS patients

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

TearScience completes $44.5 million Series C funding

TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.

5 May 2010

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.

5 May 2010

Cryo-EM images shed light on virus structure, function

UCLA researchers report in the April 30 edition of the journal Cell that they have imaged a virus structure at a resolution high enough to effectively "see" atoms, the first published instance of imaging biological complexes at such a resolution.

5 May 2010

Decisive impact of informatics on nanomedicine

According to what researchers from Facultad de Informática and other institutions have advanced in an article just published in the prestigious medical journal Pediatric Research (Vol.6, No. 5, 2010), nanoparticles are poised to play a key role in medical research in the coming decades, when nanomedicine will become part of medical practice.

5 May 2010

Principals of StemTroniX, Power3 Medical Products file patent application

StemTroniX, Inc., a Texas corporation, and Power3 Medical Products, Inc. announced today that a joint provisional patent application entitled, "Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy" has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office.

5 May 2010

Hepatitis B treatment appears to improve liver transplant outcomes for some patients: Study

Treatment to reduce recurrence of hepatitis B appears to improve liver transplant outcomes for some patients, according to a Mayo Clinic study presented at the American Transplant Congress under way May 1-5 in San Diego.

5 May 2010

Canadian Cancer Society awards London scientists new funds for innovative research

Three London scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

An estimated 26.2 percent of Americans ages 18 and older - about one in four adults - suffer from a diagnosable mental disorder every year, which equates to approximately 57.7 million adults. Severe psychiatric illness affects a much smaller number of people - about 6 percent, or 1 in 17. Worldwide, an estimated 340 million people suffer from an episode of major depression every year.

5 May 2010